The Express Scripts – AbbVie Deal Raises Concern over Patient Choices

January 12, 2015

(The Wall Street Journal) – At a time when the rising cost of medicines is causing consternation, an exclusive deal between Express Scripts, the nation’s largest pharmacy benefits manager, and AbbVie, a big drug maker, over a new hepatitis C treatment is generating concern about the implications for patient choice. The deal came after the benefits manager spent a year railing about the prices charged by Gilead Sciences, which until now has had a lock on the market.